ALK and non-small cell lung carcinoma: There are also some reports stating that, in NSCLC patients with ALK gene rearrangement, the L1196M and S1206Y substitutions in the ALK gene may be screened in liquid biopsy as possible factors of resistance to crizotinib—the first line of ALK TKI [127].